NASDAQ:FLNA Cassava Sciences (FLNA) Stock Price, News & Analysis $0.53 +0.05 (+11.15%) As of 02:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Cassava Sciences Stock (NASDAQ:FLNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cassava Sciences alerts:Sign Up Key Stats Today's Range$0.47▼$0.5450-Day Range$0.43▼$1.0352-Week Range$0.39▼$3.45Volume389,088 shsAverage Volume946,311 shsMarket Capitalization$26.87 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Cassava Sciences, Inc. is a biotechnology company focused on developing treatments and diagnostic tools for Alzheimer’s disease. The company’s Nasdaq ticker is SAVA; FLNA does not correspond to Cassava Sciences. Its research has included simufilam, an investigational oral drug candidate studied for Alzheimer’s, and SavaDX, a blood-based diagnostic program. These are products under development, not approved treatments or tests. Founded in 1998 as Pain Therapeutics, the company adopted the Cassava Sciences name in 2018. It is headquartered in Austin, Texas, and has been led by founder and chief executive Remi Barbier.AI Generated. May Contain Errors. Read More Cassava Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreFLNA MarketRank™: 2.34240212342 of 5 starsCassava Sciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 590th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCassava Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCassava Sciences has a consensus price target of $5.00, representing about 893.6% upside from its current price of $0.50.Amount of Analyst CoverageCassava Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Cassava Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.85% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 20.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cassava Sciences has recently increased by 1.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentCassava Sciences has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Healthcare companies.MarketBeat Follows3 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.5 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $356,328.00 in company stock, which represents 1.4086% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $356,328.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders4.60% of the stock of Cassava Sciences is held by insiders.Percentage Held by Institutions38.05% of the stock of Cassava Sciences is held by institutions.Read more about Cassava Sciences' insider trading history. Receive FLNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FLNA Stock News HeadlinesCassava Sciences (NASDAQ:FLNA) Stock Sees Heavy Call Option BuyingNovember 11, 2026 | americanbankingnews.comFilana Therapeutics to Participate in the 2026 Maxim Growth SummitOctober 9, 2026 | globenewswire.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 18 at 1:00 AM | Porter & Company (Ad)Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research ForwardSeptember 22, 2026 | benzinga.comFilana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related EpilepsySeptember 22, 2026 | globenewswire.comFilana Therapeutics, Inc.(NasdaqCM:FLNA) dropped from S&P Global BMI IndexSeptember 20, 2026 | marketscreener.comMDid Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?August 12, 2026 | prnewswire.comFilana Therapeutics Reports Q2 2026 Financial Results and Provides Business UpdateJuly 29, 2026 | finance.yahoo.comSee More Headlines FLNA Stock Analysis - Frequently Asked Questions How have FLNA shares performed this year? Cassava Sciences' stock was trading at $1.98 on January 1st, 2026. Since then, FLNA shares have decreased by 74.6% and is now trading at $0.5032. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:FLNA) issued its earnings results on Thursday, November, 5th. The company reported ($0.22) earnings per share for the quarter. When did Cassava Sciences' stock split? Cassava Sciences shares split on Thursday, December 21st 2023.The 14-10 split was announced on Thursday, December 21st 2023. The newly created shares were distributed to shareholders after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. How do I buy shares of Cassava Sciences? Shares of FLNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include NVIDIA (NVDA), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Plug Power (PLUG) and Block (XYZ). Company Calendar Last Earnings11/05/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 FLNA's financial health is in the Red zone, according to TradeSmith. FLNA has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:FLNA Previous SymbolNASDAQ:SAVA CIK1069530 Webcassavasciences.com Phone512-501-2444Fax512-501-0414Employees30Year Founded1998Price Target and Rating Average Price Target for Cassava Sciences$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+878.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$90.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-63.91% Return on Assets-39.19% Debt Debt-to-Equity RatioN/A Current Ratio1.91 Quick Ratio1.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.15 per share Price / Book0.44Miscellaneous Outstanding Shares50,270,000Free Float47,958,000Market Cap$25.69 million OptionableOptionable Beta-0.48 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:FLNA) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.